Merck pulled off its $10 billion buyout of Verona Pharma last month with little of the wheeling and dealing that typically ...

Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory treatment as it faces pressure to diversify beyond its blockbuster cancer drug ...

Also, this year, Verona expects to have Phase 3 data from a study of Ohtuvayre in patients with moderate-to-severe COPD. The investment bank has a buy rating and 76 price target on Verona Pharma ...

Verona Pharma plc (NASDAQ:VRNA) is one of the best multibagger stocks according to hedge funds. On July 9, 2025, Merck & Co. unveiled a $10 billion agreement to acquire Verona Pharma at $107 per ...

Verona CEO David Zaccardelli added that Merck’s commercial reach can help Ohtuvayre reach more COPD patients. COPD is a progressive disease that can cause shortness of breath, coughing and other ...

LONDON and RALEIGH, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases ...

--Verona Pharma plc announces four oral presentations and two posters on analyses from its successful Phase 3 ENHANCE studies with Ohtuvayre for the treatment of chronic obstructive pulmonary ...

Ram Selvaraju’s rating is based on the impressive performance and future prospects of Verona Pharma’s marketed product, Ohtuvayre. The company’s recent announcement of a significant revenue ...

The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make good on the deal, other secondary patents will need to hold up.

Ligand Pharmaceuticals Incorporated today announced that its partner Verona Pharma plc has received approval from the U.S. Food and Drug Administration for Ohtuvayre™. Ligand has earned a $5.8 ...

Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade ...

Pharmaceutical giant Merck is buying Verona Pharma, a company that focuses on respiratory diseases, in an approximately $10 billion deal. The deal gives Merck access to Verona Pharma's new chronic ...